HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allou

This article was originally published in The Rose Sheet

Executive Summary

Acquisition of distributor Direct Fragrances expands Allou's distribution reach to 20,000 independent retailers. The cash deal, which is cash-flow positive and anti-dilutive, provides Allou with an additional $8 mil. in revenues, the company said. Under the agreement, announced June 24, Direct Fragrances will operate as a wholly owned subsidiary with most of management remaining in place. For fiscal 1998 (ended March 31), Allou reported a sales increase of 5.8% to $301.8 mil., and a net income gain of 5.5% to $4.3 mil. The firm's Internet retailing business, The Fragrance Counter, had $900,000 in revenues during the year, with 2 mil. visitors to the site, Allou said. The distributor noted the new agreements with America On-Line, Excite, Lycos and Yahoo should increase the number of visitors to the Web site to 14 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel